2024 ICD-10-CM Diagnosis Code E85.89

Approximate Synonyms

The following clinical terms are approximate synonyms or lay terms that might be used to identify the correct diagnosis code:

• AA amyloid nephropathy
• AA amyloidosis
• Age-related amyloidosis
• AH amyloidosis
• AL amyloidosis
• AL amyloidosis
• AL amyloidosis
• ALECT2 amyloidosis
• Amyloid light chain amyloidosis due to multiple myeloma
• Amyloid myopathy
• Amyloid nephropathy
• Amyloid nephropathy
• Amyloid nephropathy
• Apolipoprotein A-IV amyloidosis
• Cerebral amyloid angiopathy
• Cerebral amyloid angiopathy associated with systemic amyloidosis
• Light chain disease
• Light chain disease
• Light chain disease
• Myeloma-associated amyloidosis
• Myeloma-associated amyloidosis
• Primary sporadic amyloid myopathy
• Primary systemic amyloidosis associated with occult plasma cell dyscrasia
• Pseudoscleroderma due to amyloid light-chain amyloidosis
• Scleroderma-like secondary cutaneous sclerosis
• Secondary systemic amyloidosis
• Secondary systemic amyloidosis
• Sporadic primary amyloidosis
• Systemic amyloidosis
• Systemic amyloidosis affecting skin

Clinical Information

• Amyloid Neuropathies, Familial

  inherited disorders of the peripheral nervous system associated with the deposition of amyloid in nerve tissue. the different clinical types based on symptoms correspond to the presence of a variety of mutations in several different proteins including transthyretin (prealbumin); apolipoprotein a-i; and gelsolin.

• Amyloidosis

  a group of sporadic, familial and/or inherited, degenerative, and infectious disease processes, linked by the common theme of abnormal protein folding and deposition of amyloid. as the amyloid deposits enlarge they displace normal tissue structures, causing disruption of function. various signs and symptoms depend on the location and size of the deposits.

• Amyloidosis, Familial

  diseases in which there is a familial pattern of amyloidosis.

• Cerebral Amyloid Angiopathy, Familial

  a familial disorder marked by amyloid deposits in the walls of small and medium sized blood vessels of cerebral cortex and meninges.

• Immunoglobulin Light-chain Amyloidosis

  a nonproliferative disorder of the plasma cell characterized by excessive production and misfolding of immunoglobulin light chains that form insoluble amyloid fibrils (see amyloid deposits) in various tissues. clinical features include liver failure; multiple myeloma; nephrotic syndrome; restrictive cardiomyopathy, and neuropathies.

• Cerebral Amyloid Angiopathy

  a heterogeneous group of sporadic or familial disorders characterized by amyloid deposits in the walls of small and medium sized blood vessels of cerebral cortex and meninges. clinical features include multiple, small lobar cerebral hemorrhage; cerebral ischemia (brain ischemia); and cerebral infarction. cerebral amyloid angiopathy is unrelated to generalized amyloidosis. amyloidogenic peptides in this condition are nearly always the same ones found in alzheimer disease. (from kumar: robbins and cotran: pathologic basis of disease, 7th ed., 2005)

• Amyloid

  a fibrous protein complex that consists of proteins folded into a specific cross beta-pleated sheet structure. this fibrillar structure has been found as an alternative folding pattern for a variety of functional proteins. deposits of amyloid in the form of amyloid plaques are associated with a variety of degenerative diseases. the amyloid structure has also been found in a number of functional proteins that are unrelated to disease.

• AH Amyloidosis

  a rare type of amyloidosis characterized by the monoclonal deposition of immunoglobulin heavy chain fragments in organs and tissues. it is associated with plasma cell or b-cell lymphoproliferative disorders.

• Cerebral Amyloid Angiopathy

  a disorder characterized by the deposition of amyloid in the wall of the vessels in the brain.

• Cerebral Amyloid Angiopathy, APP-Related|HCHWAD|Hereditary Cerebral Hemorrhage with Amyloidosis-Dutch Type

  an autosomal dominant form of cerebral amyloid angiopathy caused by mutation(s) in the app gene, encoding amyloid-beta a4 protein. the deposition of amyloid in cerebral blood vessels wall may lead to degenerative vascular changes that may result in cerebral hemorrhage. mutation(s) in the app gene may also cause autosomal dominant alzheimer disease 1.

E85.89 is grouped with Diagnostic Related Groups - MS-DRG Mapping

Diagnostic Related Groups (DRGs) are a classification system used to group together diagnosis codes for the purpose of reimbursement and healthcare management. DRGs are used to standardize the way hospitals and other providers are paid for inpatient services. In this system patients are grouped together based on their principal diagnosis in areas referred to as Major Diagnostic Categories (MDC). Once a patient is assigned a particular diagnostic category, providers receive a predetermined payment rate for the services rendered. This reimbursement rate is often fixed and is meant to cover the cost of care for that patient. Reimbursement is also affected by the relative weight of a diagnostic related group based on the severity of a patient's illness and the associated cost of care during hospitalization.

Diagnostic related groups encourage healthcare providers to focus on quality and efficiency in patient care while managing costs effectively. The diagnosis code is present in the following groups for version MS-DRG V41.0 applicable from 10/01/2023 through 09/30/2024.

The relative weight of a diagnostic related group determines the reimbursement rate based on the severity of a patient's illness and the associated cost of care during hospitalization.

Replacement Code

E8589 replaces the following previously assigned ICD-10-CM code(s):

• E85.8 - Other amyloidosis

Convert E85.89 to ICD-9-CM

• ICD-9-CM Code: 277.39 - Amyloidosis NEC
  Approximate Flag - The approximate mapping means there is not an exact match between the ICD-10 and ICD-9 codes and the mapped code is not a precise representation of the original code.

Code History

• FY 2024 - No Change, effective from 10/1/2023 through 9/30/2024
• FY 2023 - No Change, effective from 10/1/2022 through 9/30/2023
• FY 2022 - No Change, effective from 10/1/2021 through 9/30/2022
• FY 2021 - No Change, effective from 10/1/2020 through 9/30/2021
• FY 2020 - No Change, effective from 10/1/2019 through 9/30/2020
• FY 2019 - No Change, effective from 10/1/2018 through 9/30/2019
• FY 2018 - No Change, effective from 10/1/2017 through 9/30/2018